Full-Time

Associate Director

HCP Marketing

Posted on 9/10/2026

argenx

argenx

1,001-5,000 employees

Biotech immunology company developing therapeutic antibodies

No salary listed

Boston, MA, USA

Hybrid

Must be in the US; Boston-based organization; office presence as needed; travel ~30%.

Bachelor's, MBA

Category
Growth & Marketing (1)
Required Skills
Market Research

Get referred to argenx

See people who can refer or advise you

Requirements
  • The US commercial organization is Boston-based; this person must be in the office as needed to support key planning and coordination meetings
  • BS/BA degree (science or business degree preferred)
Responsibilities
  • Contribute to the development and execution of disease state education and branded positioning, campaign, and messaging across personal and non-personal channels
  • Develop and lead media strategy to drive unbranded and branded engagement across digital and non-personal channels
  • Execute HCP Advisory Board and Market Research planning and execution to generate and synthesize relevant customer insights to inform message and tactical evolution
  • Define, monitor, and evolve KPIs to assess performance and guide strategic adjustments
  • Execute multiple, simultaneous projects and manage resources to ensure deliverables are on time, on budget, and address business objectives
  • Engagement with key agency partners, including AOR, P2P, Media in the development and execution of market development and branded campaigns and tactics
  • Represent argenx at industry conferences and build relationships with key opinion leaders and other key stakeholders
  • Collaborate and co-create with multiple functional groups within the organization to effectively navigate the promotional review process, prioritize and ensure timely and compliant development of HCP-directed tactics
Desired Qualifications
  • MBA is a plus
  • Experience in rheumatology preferred
  • US launch readiness experience preferred

argenx develops antibody therapies to treat autoimmune diseases and cancer by translating scientific discoveries in immunology into therapeutic antibodies. Its work centers on R&D and then licensing and collaborations for commercialization, with cusatuzumab being developed with Janssen R&D to target hematological cancers such as leukemia. The company funds and accelerates discovery mainly through partnerships and licenses, bringing products to market via partner-based commercialization rather than building its own sales force. Its goal is to advance antibody-based treatments for serious autoimmune diseases and cancer by turning scientific insights into clinically useful therapies through industry and academic collaborations.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Ghent, Belgium

Founded

2008

Get referred to argenx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 60% year over year to $1.54 billion.
  • August 17, 2026 ALKIVIA Phase 3 showed positive autoimmune myositis results, expanding the franchise.
  • BenchSci signed a two-year enterprise deal with argenx, signaling continued R&D investment and adoption.

What critics are saying

  • FDA issued two January 30, 2026 untitled letters for misleading VYVGART Hytrulo TV ads.
  • VYVGART still drives most revenue, so any launch stumble hits growth immediately.
  • FB102 needs celiac and alopecia data in 2026; failure weakens the $2.2 billion Forte bet.

What makes argenx unique

  • VYVGART became first approved gMG therapy across all serotypes on May 8, 2026.
  • argenx's SIMPLE Antibody platform and FcRn expertise create a durable discovery-to-commercialization moat.
  • August 27, 2026 Forte acquisition added FB102, deepening differentiated CD122 immunology coverage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Montreal Gazette
Sep 2nd, 2026
BenchSci announces two-year enterprise agreement with argenx to advance ai-driven preclinical drug discovery.

BenchSci announces two-year enterprise agreement with argenx to advance ai-driven preclinical drug discovery. Scientist-led competitive selection deepens BenchSci's presence in European biopharma TORONTO - BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization. Selected through a competitive evaluation...

Yahoo Finance
Sep 2nd, 2026
Argenx posts 18 consecutive quarters of sales growth, Q2 2026 revenue up 60% YoY

Argenx has achieved 18 consecutive quarters of revenue growth, with second-quarter 2026 sales rising 60% year-over-year and 17% sequentially. The biotech's Vyvgart and Vyvgart Hytrulo therapies continue gaining traction in treating severe autoimmune diseases. Earnings reached $472 million in Q2, nearly double the prior year, with expanding operating margins. The company holds approvals in generalised myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. Argenx recently reported positive late-stage results for Vyvgart Hytrulo in autoimmune myositis, affecting around 100,000 Americans. Management sees this as a multibillion-dollar opportunity. The company expects Phase 3 results for empasiprubart in multifocal motor neuropathy during Q4 2026. CFO Karl Gubitz noted only 20% of gMG patients currently receive novel biologics, suggesting significant growth potential.

wallstreet:online AG
Aug 21st, 2026
Not Moderna: this biotech stock still has potential after an 11,000% rally!

Not Moderna: this biotech stock still has potential after an 11,000% rally! Since its IPO in 2014, the Argenx stock has risen by more than 11,150 percent. A study success is fueling new enthusiasm for Argenx. The background. Photo: Andrew Brookes - Westend61 Europe's largest listed pure-play biotech group currently knows only one direction: upwards. The Argenx stock has gained 21 percent since last Friday's closing price, marked a record high and is heading for its best week in more than three years. This puts it at the top of the winners in the Stoxx Europe 600, reports Bloomberg. The long-term record is even more spectacular: Since the Brussels listing in July 2014, the price has shot up by more than 11,150 percent. The market capitalization climbed to 55.4 billion euros - putting Argenx ahead of Moderna again. Trade your assessment of BioNTech SE ADR!

Yahoo Finance
Aug 18th, 2026
Argenx rises 11.5% after positive phase 3 trial for autoimmune myositis treatment

argenx reported positive Phase 3 results for its ALKIVIA trial evaluating VYVGART Hytrulo in adults with autoimmune myositis. The trial met its primary endpoint, with patients showing statistically significant improvements in Total Improvement Score over 52 weeks versus placebo. The study marks the first Phase 3 trial demonstrating benefit in immune-mediated necrotizing myopathy, a subtype with no approved targeted therapies. The safety profile remained consistent with prior studies. The company recently received US FDA priority review for VYVGART in seronegative generalized myasthenia gravis, with a decision expected on 10 May 2026. These label expansions could broaden VYVGART's reach across multiple autoimmune conditions. argenx's shares rose 11.5% following the announcement. The company's narrative projects $9.7 billion revenue and $3.5 billion earnings by 2029, requiring 22.3% yearly revenue growth.

Yahoo Finance
Aug 11th, 2026
argenx shares up 39% in a year, but analysts debate $775 fair value vs $867 close

argenx, a commercial-stage biopharma company specialising in autoimmune disease treatments, has attracted investor attention following recent share price movements. The stock closed at €767, up approximately 6% over the past week and 38.6% over the past year, bringing its market value to around €47.97 billion. The company generates revenue of €5.3 billion, primarily from its VYVGART franchise, with operations spanning the United States, Japan, China, and other markets. According to a widely followed valuation narrative, argenx appears 11.7% overvalued, with a fair value estimate of €686.43. The analysis credits the company's leadership in FcRn inhibitors and strong commercial growth, whilst noting typical biotech risks including single-asset dependence and pricing pressure. Revenue has doubled over two years, supporting the growth thesis.